𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas

✍ Scribed by Simona Bortolotto; Loredana Chiadò-Piat; Paola Cavalla; Ivana Bosone; Adriano Chiò; Alessandro Mauro; Davide Schiffer

Publisher
John Wiley and Sons
Year
2000
Tongue
French
Weight
179 KB
Volume
88
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Inactivation of p16/CDKN2 and p15/MTS2 i
Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer
✍ Kazuya Kudoh; Yoshihito Ichikawa; Sadao Yoshida; Misako Hirai; Yoshihiro Kikuchi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 130 KB

## Abstract To define the involvement of __p16/CDKN2__ and __p15/MTS2__ tumor‐suppressor genes for response to chemotherapy in primary epithelial ovarian cancer, we analyzed alterations of the gene in 45 patients who were treated with primary cytoreductive surgery followed by 6 courses of cis‐diamm

p16 inactivation in small-sized lung ade
p16 inactivation in small-sized lung adenocarcinoma: Its association with poor prognosis
✍ Beniyo Kawabuchi; Sachiko Moriyama; Mitsugu Hironaka; Takeshi Fujii; Morio Koike 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 105 KB

p16, an inhibitor of cell cycle machinery, is frequently inactivated in non-small cell carcinoma of the lung (NSCCL). To clarify the significance of p16 inactivation in the progression of lung adenocarcinoma, we immunohistochemically evaluated p16 protein status and Rb, p53 and cyclin D1 expression

Association of CDKN2A (p16)/CDKN2B (p15)
Association of CDKN2A (p16)/CDKN2B (p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma
✍ Kunihiro Hamada; Takashi Kohno; Masashi Kawanishi; Susumu Ohwada; Jun Yokota 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB 👁 1 views

To elucidate the possibility of the existence of multiple tumor suppressor genes on chromosome arm 9p, we performed genetic and epigenetic analyses of the CDKN2A/p16/MTS1 and CDKN2B/p15/MTS2 genes as well as homozygous deletion mapping of 9p in human lung carcinoma. To avoid overlooking genetic alte

Low frequency of p16/CDKN2 gene mutation
Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas
✍ Asunción Esteve; Ghyslaine Martel-Planche; Bakary S. Sylla; Monica Hollstein; Pi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 515 KB

Mutational analysis of the pl6ICDKN2 gene was conducted by direct sequencing of the whole coding sequence (exom 1-3 and flanking splicing sites) in 21 esophageal squamous-cell carcinomas and 3 adenocarcinomas from a high-incidence area of Italy. Two inactivating mutations were found in exon I of the

Alterations of CDKN2 (p16) in non-small
Alterations of CDKN2 (p16) in non-small cell lung cancer
✍ Sven De Vos; Carl W. Miller; Seisho Takeuchi; Adrian F. Gombart; Steve K. Cho; H 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 567 KB

## Abstract The cyclin‐dependent kinase inhibitor known as __p16__ (__CDK41, CDKN2, INK4A, MTS1__) has been proposed as a tumor suppressor gene on chromosome segment 9p21. We have evaluated __CDKN2__ alterations in 34 non‐small cell lung cancers (NSCLCs) with matched normal tissue controls and in 9